論文・技術情報追加のお知らせ

1. The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.

エンパグリフロジンに関連する新たな副作用として膵炎、胃腸炎、脳梗塞が確認

対象DB：FAERS

2. Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.

心膜液貯留リスクがダサチニブ、メサラジン、ヒドララジンで高い

対象DB：FAERS

3. Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system.

ICI治療薬間で副作用の違いがあり、薬剤選択時の考慮が重要

対象DB：FAERS

4. Adverse drug event profile of pharmacotherapies for alcohol use disorder: a retrospective pharmacovigilance disproportionality analysis study.

アルコール使用障害薬の副作用を分析し、安全性向上に必要な監視を強調

対象DB：FAERS

5. A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database.

ボリコナゾール、ポサコナゾール、isavuconazoleに関連する副作用シグナルを比較

対象DB：FAERS

6. Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.

オファツムマブで脳霧や筋肉痙攣など新たな副作用が確認された

対象DB：FAERS

7. The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

オファツムマブに関連する副作用、特に疲労や頭痛などが報告

対象DB：FAERS

8. Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system.

バンコマイシンなどの抗生物質がLABDと関連

対象DB：FAERS

9. A real-world pharmacovigilance study of Sacubitrilvalsartan in older people: data mining of the FDA adverse event reporting system.

サクビトリルバルサルタン、高齢者で新たな安全性シグナル

対象DB：FAERS

10. Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer.

アミバンタマブの有害事象は初月に多発

対象DB：FAERS

11. Adverse events in the nervous system associated with blinatumomab: a real-world study.

ブリナツモマブの神経毒性は若年層で多発

対象DB：FAERS

12. Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database.

ニトロフラントインやミノサイクリンが自己免疫性肝炎と関連

対象DB：FAERS

13. Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting system.

ルスパテルセプトは調製ミスや急性肝炎に注意

対象DB：FAERS

14. A real-world pharmacovigilance study of blinatumomab based on the FDA adverse event reporting system.

ブリナツモマブは移植片対宿主病などの有害事象に注意

対象DB：FAERS

15. Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS.

小児のチサゲンレクロイセルは心血管有害事象に注意

対象DB：FAERS

16. A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic.

特定の薬剤11種が天疱瘡発症と有意に関連

対象DB：FAERS

17. Safety assessment of selinexor: a real-world pharmacovigilance study.

セリネキソルの副作用を解析し新規リスクを特定

対象DB：FAERS

18. Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024.

RZVワクチンの安全性に関するデータを提供

対象DB：FAERS,VAERS

19. Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.

GLP-1受容体作動薬での神経精神的有害事象を特定

対象DB：FAERS

20. Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database.

セツキシマブ使用に関連する新たな有害事象シグナルを特定

対象DB：FAERS

21. Analysis of immune related adverse events of pembrolizumab using FAERS database.

ペムブロリズマブの免疫関連有害事象、年齢・性別差が重要

対象DB：FAERS

22. Cyclin-dependent kinase 4/6 inhibitor-associated pulmonary toxicity: a disproportionality analysis from 2015 to 2023 based on the FAERS database.

CDK4/6阻害剤の肺毒性、特にアベマシクリブに関連

対象DB：FAERS

23. Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database.

ナルトレキソンによる副作用のリスクをFAERSで分析

対象DB：FAERS

24. Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database.

薬剤による鼻中隔穿孔のリスクをFAERSで分析

対象DB：FAERS

25. Self-Organizing Map-Based Assessment of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.

ICIsによる免疫関連有害事象をSOMと決定木で解析

対象DB：JADER

26. Trends in Reports of Statin-Associated Immune-Mediated Necrotizing Myopathy Using the Japanese Adverse Drug Event Report Database.

スタチン関連の免疫媒介性壊死性筋ジストロフィーが警告改訂後に増加

対象DB：JADER,JMDC

27. Disproportionality Analysis of Hypotension-Related Adverse Drug Reactions Associated with Type 1a Selective Alpha Blockers in VigiBase.

選択的T1aαブロッカーは若年女性と高齢男性において低血圧関連ADRのリスク増加と関連

対象DB：VigiBase

28. Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).

アロマターゼ阻害薬と認知症、アルツハイマー病の関連が示唆

対象DB：VigiBase

29. PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database.

免疫チェックポイント阻害薬は移植片拒絶反応と関連

対象DB：VigiBase

30. Lichenoid drug eruption and apalutamide: Analyses from pharmacovigilance databases and disproportionality analysis.

アパルタミドの皮膚毒性はLDEとして現れ、中止で改善

対象DB：FPVD,VigiBase

31. Seizure after flumazenil reversal for total intravenous anaesthesia with remimazolam versus propofol: a matched retrospective cohort analysis of a large Japanese nationwide inpatient database.

レミマゾラム-フルマゼニルとプロポフォールで術中発作の発生に有意差なし

対象DB：DPC

32. Predictive Validity of Hospital-Associated Complications of Older People Identified Using Diagnosis Procedure Combination Data From an Acute Care Hospital in Japan: Observational Study.

HAC-OP-DPCは高齢者入院の予測因子として有効

対象DB：DPC

33. Effectiveness of an Impella Versus Intra-Aortic Balloon Pump in Patients Who Received Extracorporeal Membrane Oxygenation.

ECMOとIABP併用治療の比較研究

対象DB：DPC

34. Determination of Lifestyle Habits Correlating to the Prevalence of Hypertension, Diabetes, and Dyslipidemia by the Analysis of Health-Related Questionnaire Datasets in Japanese Nationwide Open Data.

喫煙、体重増加、食習慣が高血圧、糖尿病に関連

対象DB：NDB

35. Outcomes of COVID-19 in the Omicron-predominant wave: large-scale real-world data analysis with a comparison to influenza.

オミクロン株流行期、COVID-19死亡率は低下も高齢者の死亡数は増加

対象DB：NDB

36. Development and validation of a prediction model for serious infections in rheumatoid arthritis patients treated with tocilizumab in Japan.

トシリズマブ使用RA患者の重症感染予測モデルを開発

対象DB：MDV

37. Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022.

ASCTの医療費と主要因を全国調査

対象DB：MDV

38. Adverse childhood experiences in firstborns and mental health risk and health-care use in siblings: a population-based birth cohort study of half a million children in England.

第1子のACEsが家族全体の精神健康に影響

対象DB：CPRD

39. The Clinical Practice Research Datalink (CPRD) Mother-Baby Links: A Data Resource Profile.

母子リンクデータは妊娠中の影響研究に有用

対象DB：CPRD

40. The impact of polypharmacy on health outcomes in the aged: A retrospective cohort study.

高齢者の多剤併用は死亡率と入院リスクを増加

対象DB：CPRD

41. Analysis of medical practices used as indicators in the fourth basic plan for the promotion of cancer control in Japan.

がん患者の医療実態を請求データで分析

対象DB：DeSC

42. The relationship between depression and cardiovascular disease in older people: results from a large-scale epidemiological cohort study in Japan.

高齢者のうつ病は心血管疾患リスクを増加させる

対象DB：DeSC